'Moody' Analysts Upbeat About Quintiles

By Dan Stanton

- Last updated on GMT

Related tags Stock market Stock

'Moody' Analysts Upbeat About Quintiles
Analysts from rating agency Moody's have upgraded their view of Quintiles, the world’s “largest pharmaceutical service provider,” from stable to positive.

Quintiles rejoined the market it left in 2003 when it went public in May​ after raising more than $1bn (€760m) in its IPO.

Two months on and investment firm Moody’s Investors Services has changed its outlook on Quintiles to positive, citing the firm’s “size, scale and leading position as both a pharmaceutical CRO and a contract sales organization.

“Quintiles, as the largest pharmaceutical service provider, is well-positioned to gain market share and benefit from the industry's growth, the outlook for which is favorable, as pharmaceutical companies look to outsource an increasing portion of their non-core functions.”

Moody’s acknowledged Quintiles - headquartered in Durham, North Carolina – repayment of $350m of debt with proceeds from the IPO, its “significant”​ cash balance and free cash flow expectation of at least $200m per year.

In June a number of other investment analysts gave their verdicts on Quintiles with a mostly positive or neutral outlook​.

Speaking at the time, Tim Evans of Wells Fargo – who gave an outlook of ‘outperform’ and a stock price target of $49 – described Quintiles as “one of the industry’s most disciplined operators”​ predicting the firm “will continue capturing share from small contract research organisations.”

Following the return to the market in May, Quintiles inked a five year exclusive clinical development agreement with Merck-Serono.

Related news

Show more

Related products

show more

Using Define-XML to build more efficient studies

Using Define-XML to build more efficient studies

Content provided by Formedix | 14-Nov-2023 | White Paper

It is commonly thought that Define-XML is simply a dataset descriptor: a way to document what datasets look like, including the names and labels of datasets...

Overcoming rapid growth challenges with process liquid preparation

Overcoming rapid growth challenges with process liquid preparation

Content provided by Thermo Fisher Scientific - Process Liquid Preparation Services | 01-Nov-2023 | Case Study

A growing contract development manufacturing organization (CDMO) was challenged with the need to quickly expand their process liquid and buffer preparation...

Why should you use clinical trial technology?

Why should you use clinical trial technology?

Content provided by Formedix | 01-Nov-2023 | White Paper

New, innovative clinical trial technology is helping to revolutionize the research landscape. COVID-19 demonstrated that clinical trials can be run much...

Related suppliers

Follow us


View more